Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932628 | 0.79 | — | — | |
| SCHEMBL2909351 | 0.75 | MGAM (0.46) | CHRM1CA12CA1CA2CA9 | |
| SCHEMBL21488882 | 0.73 | CHRM1 (0.37) | CHRM1CA12CA1CA2CA9 | |
| SCHEMBL7668945 | 0.71 | CA12 (0.64) | CHRM1CA12CA1CA2CA9 | |
| SCHEMBL6102651 | 0.71 | OPRK1 (0.38) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18342946 | 0.71 | KMT2A (0.36) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL21667825 | 0.70 | TSHR (0.42) | CHRM1CA12CA1CA2CA9 | |
| SCHEMBL2803666 | 0.70 | GAA (0.35) | CHRM1CA12CA1CA2CA9 | |
| SCHEMBL2840542 | 0.68 | CA12 (0.46) | CHRM1CA12CA1CA2CA9 | |
| SCHEMBL2804678 | 0.68 | CA12 (0.41) | CHRM1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2019-10-24 | — | — | US | claimed |
| EP-4384145-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2024-06-19 | — | — | EP | disclosed |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-09-14 | — | — | US | disclosed |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-03-30 | — | — | US | disclosed |
| WO-2023018966-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322618-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | CHRM1 2113/4885CA12 4848/4885CA1 4399/4885 |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | CHRM1 612/4885CA12 4117/4885CA1 2641/4885 |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | CHRM1 612/4885CA12 4117/4885CA1 2641/4885 |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | CHRM1 612/4885CA12 4117/4885CA1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.